Fortress Biotech Inc
CNB0
Company Profile
Business description
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
Contact
1111 Kane Concourse
Suite 301
Bay Harbor IslandFL33154
USAT: +1 781 652-4500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
78
Stocks News & Analysis
stocks
The ASX player evolving into a defensive haven
A well-timed simplification journey as boring evolves back in vogue.
stocks
12 picks for an income portfolio - Q1 2026 update
Passive income growth continues to exceed my target.
stocks
Strong guidance from undervalued ASX share
Shares surged after the announcement of first half fiscal 2026 guidance.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,174.10 | 12.00 | 0.13% |
| CAC 40 | 8,338.98 | 86.15 | -1.02% |
| DAX 40 | 24,469.30 | 232.94 | -0.94% |
| Dow JONES (US) | 49,428.49 | 18.94 | -0.04% |
| FTSE 100 | 10,620.08 | 47.55 | -0.45% |
| HKSE | 26,361.07 | 200.74 | 0.77% |
| NASDAQ | 24,367.85 | 100.63 | -0.41% |
| Nikkei 225 | 58,824.89 | 348.99 | 0.60% |
| NZX 50 Index | 12,915.45 | 9.78 | 0.08% |
| S&P 500 | 7,112.66 | 13.40 | -0.19% |
| S&P/ASX 200 | 8,953.30 | 13.60 | 0.15% |
| SSE Composite Index | 4,082.13 | 30.70 | 0.76% |